Ibex Medical Analytics has launched a Biopharma Advisory Board, appointing Dr. Ruth March and Dr. Paolo Tarantino as its inaugural members. This initiative aims to enhance AI-driven biomarker development and precision diagnostics in the biopharma sector.
The establishment of the Advisory Board underscores Ibex's strategic move into biopharma, focusing on the increasing demand for precise biomarker quantification, especially as oncology trends toward targeted therapies like antibody-drug conjugates (ADCs). The Board will offer scientific and strategic insights as Ibex aims to support partners throughout the lifecycle of biomarker development and AI-powered companion diagnostics.
Dr. March, previously a Senior Vice President at AstraZeneca, is recognized for her pioneering work in precision medicine, leading the approval of numerous companion diagnostics and advancing genomics initiatives. Dr. Tarantino, a breast oncologist at Dana-Farber Cancer Institute, is known for his research on ADCs and predictive biomarkers in breast cancer treatment.
This new advisory structure is set to enhance Ibex's Biopharma Services, which have already demonstrated success in developing and deploying AI-driven diagnostics. As the landscape of cancer treatment evolves, the integration of AI in diagnostics will be crucial for improving patient outcomes and streamlining clinical development processes.